Indivior PLC (NASDAQ:INDV) Shares Acquired by Millennium Management LLC

Millennium Management LLC grew its stake in shares of Indivior PLC (NASDAQ:INDV - Free Report) by 36.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,233,006 shares of the company's stock after acquiring an additional 332,180 shares during the quarter. Millennium Management LLC owned about 0.89% of Indivior worth $15,326,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Deerfield Management Company L.P. Series C lifted its holdings in Indivior by 74.4% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 8,883,160 shares of the company's stock valued at $110,418,000 after purchasing an additional 3,790,518 shares in the last quarter. Claret Asset Management Corp bought a new position in shares of Indivior in the fourth quarter worth about $9,304,000. CenterBook Partners LP increased its holdings in shares of Indivior by 105.5% in the 4th quarter. CenterBook Partners LP now owns 1,147,841 shares of the company's stock valued at $14,268,000 after acquiring an additional 589,158 shares during the period. Marshall Wace LLP boosted its holdings in shares of Indivior by 659.7% in the 4th quarter. Marshall Wace LLP now owns 506,782 shares of the company's stock valued at $6,299,000 after buying an additional 440,072 shares in the last quarter. Finally, Foursixthree Capital LP purchased a new position in shares of Indivior in the 4th quarter valued at approximately $4,639,000. Hedge funds and other institutional investors own 60.33% of the company's stock.

Indivior Stock Performance

INDV stock traded up $0.22 during midday trading on Wednesday, reaching $12.05. 162,863 shares of the company were exchanged, compared to its average volume of 1,021,392. The company has a market cap of $1.66 billion, a price-to-earnings ratio of -34.25 and a beta of 0.98. The stock's 50-day simple moving average is $10.34 and its 200 day simple moving average is $10.72. Indivior PLC has a 1-year low of $7.33 and a 1-year high of $18.59.

Indivior (NASDAQ:INDV - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The company reported $0.41 earnings per share for the quarter, beating analysts' consensus estimates of $0.22 by $0.19. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%. The firm had revenue of $266.00 million for the quarter, compared to analyst estimates of $240.13 million. On average, research analysts anticipate that Indivior PLC will post 1.22 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on INDV. RODMAN&RENSHAW raised shares of Indivior to a "strong-buy" rating in a research report on Tuesday, January 28th. Rodman & Renshaw initiated coverage on Indivior in a report on Tuesday, January 28th. They set a "buy" rating and a $16.00 target price on the stock. Finally, Piper Sandler decreased their target price on shares of Indivior from $16.00 to $13.00 and set an "overweight" rating on the stock in a research report on Thursday, March 6th.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.